Technical Analysis for TNFA - TNF Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 180 Bearish Setup | Bearish Swing Setup | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| MACD Bearish Centerline Cross | Bearish | -6.34% | |
| Hammer Candlestick | Bullish | -6.34% | |
| Lizard Bullish | Bullish Day Trade Setup | -6.34% |
| Alert | Time |
|---|---|
| Down 5% | about 15 hours ago |
| Fell Below Previous Day's Low | about 15 hours ago |
| Down 3% | about 17 hours ago |
| Fell Below Lower Bollinger Band | about 17 hours ago |
| Down 2 % | about 17 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: Unknown
TNF Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which engages in the development of drug products targeting aging, age-related, and autoimmune diseases, chronic pain, anxiety, and sleep disorders. It focuses on developing and commercializing the MyMD-1 and SUPERA-CBD therapeutic platforms. MyMD-1 is a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune diseases. Supera-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in Baltimore, MD.
Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Pain Autoimmune Disease Disorders Chronic Pain Depression Epilepsy Analgesics Drug Products Cannabidiol Neurodegenerative Disease Sjögren Syndrome Anticonvulsants
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Pain Autoimmune Disease Disorders Chronic Pain Depression Epilepsy Analgesics Drug Products Cannabidiol Neurodegenerative Disease Sjögren Syndrome Anticonvulsants
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.16 |
| 52 Week Low | 1.1601 |
| Average Volume | 35,882 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 1.58 |
| 20-Day Moving Average | 1.61 |
| 10-Day Moving Average | 1.59 |
| Average True Range | 0.16 |
| RSI (14) | 39.02 |
| ADX | 21.74 |
| +DI | 16.82 |
| -DI | 21.50 |
| Chandelier Exit (Long, 3 ATRs) | 1.46 |
| Chandelier Exit (Short, 3 ATRs) | 1.81 |
| Upper Bollinger Bands | 1.87 |
| Lower Bollinger Band | 1.35 |
| Percent B (%b) | -0.04 |
| BandWidth | 32.28 |
| MACD Line | -0.03 |
| MACD Signal Line | 0.01 |
| MACD Histogram | -0.039 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.50 | ||||
| Resistance 3 (R3) | 1.52 | 1.47 | 1.47 | ||
| Resistance 2 (R2) | 1.47 | 1.43 | 1.47 | 1.46 | |
| Resistance 1 (R1) | 1.40 | 1.40 | 1.38 | 1.39 | 1.45 |
| Pivot Point | 1.36 | 1.36 | 1.35 | 1.35 | 1.36 |
| Support 1 (S1) | 1.29 | 1.31 | 1.27 | 1.27 | 1.21 |
| Support 2 (S2) | 1.24 | 1.29 | 1.24 | 1.20 | |
| Support 3 (S3) | 1.17 | 1.24 | 1.19 | ||
| Support 4 (S4) | 1.16 |
